Rush's Head and Neck Cancer Program provides comprehensive care for patients with benign and malignant head and neck tumors. Our multidisciplinary team includes head and neck surgeons, medical oncologists, plastic surgeons, radiation oncologists, skull base surgeons and allied health providers, including nurses, dietitians, speech pathologists, occupational therapists and physical therapists.

Our head and neck surgeons are recognized nationally for their care and have expertise treating a wide range of conditions, including early-stage, advanced and recurrent tumors. Our team delivers the latest treatments, radiation therapies, minimally invasive surgeries, and clinical trials. Patients have easy access to our physicians and second opinion services.

Our Capabilities

Microvascular Reconstruction Surgery
Our surgeons use patients’ healthy blood vessels, bone and tissue to rebuild defects of the face and neck caused by the removal of tumors. Microvascular reconstruction and state-of-the-art virtual surgical planning capabilities allow our surgeons to precisely correct defects from cancer treatment or contour irregularities.

Transoral Robotic Surgery
Transoral Robotic Surgery (TORS) is used to safely remove benign and malignant tumors of the mouth and throat. This minimally invasive surgical method is recognized as the new standard of care for head and neck cancer patients. Patients can expect a quicker recovery time compared to traditional surgical procedures.

Enhanced Recovery After Surgery
An enhanced recovery after surgery (ERAS) protocol is used to optimize patients’ experience. We are able to discharge most patients without opioids.

Tempus
Rush partners with Tempus to gain a better understanding of the genetics of cancerous tumors and which treatment approaches specific tumors will respond to. Genetic analysis is recommended for patients who have run out of treatment options, and those with rare cancers, such as skull base tumors and salivary gland cancers.

Organ Preservation
Head and neck cancers can be treated with radiation therapy and chemotherapy to preserve organs and their functions.

Speech and Swallowing Support
Advanced technology is used to diagnose and treat swallowing disorders, including videofluoroscopy and fiberoptic endoscopic evaluation of swallowing (FEES). Frequent support and therapy is provided during and after treatment to help patients maintain and return to normal function. Complete laryngectomy care services are also provided with expertise in tracheoesophageal voice prosthesis care and management.

Conditions We Treat
- Head and neck skin cancers and melanoma
- HPV-associated oropharyngeal cancer
- Laryngeal and pharyngeal cancer
- Oral cavity cancer
- Thyroid cancer
- Nasopharyngeal cancer
- Salivary gland cancer
- Skull base cancer

Nationally Ranked Programs
The oncology team at Rush University Medical Center is consistently ranked among the best in the country in U.S. News & World Report. Rush is currently ranked 48th out of more than 3,000 hospitals in the country for adult cancer care services, and 47th for ear, nose and throat services. Overall, Rush University Medical Center is ranked 17th in the country, on the Best Hospitals Honor Roll, and 2nd in Illinois and Chicago.
Our Team

Head and Neck Surgeons

Samer Al-Khudari, MD
Kerstin M. Stenson, MD
Mihir K. Bhayani, MD

Radiation Oncologist

Nikhil Joshi, MD

Medical Oncologists

Mary Jo J. Fidler, MD
Michael J. Jelinek, MD

Skull Base Surgeons

Pete S. Batra, MD
Bobby A. Tajudeen, MD

Facial Plastic and Reconstructive Surgeons

Peter C. Revenaugh, MD
Ryan M. Smith, MD

Speech-Language Pathologist

Josh Teitcher, MS, CCC-SLP

Locations

Rush University Cancer Center
Professional Building
1725 W. Harrison St.
Chicago, IL 60612

Rush Otorhinolaryngology, Head and Neck Surgery
Sofija and Jorge O. Galante Orthopedic Building
1611 W. Harrison St.
Chicago, IL 60612

Rush Cancer Care in Oak Park
Rush Oak Park Hospital
Medical Office Building
610 S. Maple Ave., Suite 5400
Oak Park, IL 60304

Rush Oak Brook
2011 York Road
Oak Brook, IL 60523

Learn more: rush.edu/cancer